Trump Administration Reclassifies Medical Marijuana to Schedule III

In Brief

The reclassification of medical marijuana may affect research, regulation, and legal status for patients and providers.

Key Facts

• Acting Attorney General Todd Blanche announced the immediate move of medical marijuana from Schedule I to Schedule III.
• Schedule III includes drugs such as ketamine, Tylenol with codeine, and anabolic steroids.
• The reclassification applies specifically to state-licensed medical marijuana.
• This marks a shift from previous federal policy, which classified marijuana as a Schedule I substance.
• Multiple news outlets described the move as a historic change in U.S. drug policy.

What Happened

The Trump administration announced that medical marijuana will be moved from Schedule I to Schedule III, changing its federal classification and regulatory status.

Why It Matters

This change could impact medical research, patient access, and the legal landscape for medical marijuana providers, potentially easing restrictions at the federal level.

What's Next

Observers are watching for regulatory updates, potential changes in enforcement, and how states and medical providers respond to the new classification.